Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C-heparin is a cleaved, low-affinity form of heparin, a sulfated polysaccharide. It is prepared through the partial deaminative cleavage of commercial crude heparin. This modified heparin exhibits anticoagulant activity primarily by inhibiting factor Xa. Additionally, C-heparin has been shown to interact with cytochrome c, influencing its thermotropic properties and inhibiting electron transport from reduced cytochrome c to cytochrome c oxidase. It has been studied for its potential in surface modification, specifically for immobilization onto pyrolytic carbon-coated graphite used in mechanical heart valve prostheses, where it retains anticoagulant activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on C-heparin.